Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
Celcuity reported positive Phase 3 topline results for the PIK3CA mutant cohort in its pivotal VIKTORIA-1 trial, showing statistically significant improvement in progression-free survival for gedatolisib regimens compared to alpelisib. The company intends to submit a supplemental New Drug Application (sNDA) to the FDA in Q3 2026, aiming for potential approval and commercial launch in the third quarter of 2026.
Key figures
- Revenue
- 0
- Rd expenses
- 33063000
- Sga expenses
- 17444000
- Operating expenses
- 50507000
- Weighted avg shares
- 54462826
- Cash and equivalents
- 387100000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.